Jennison Associates
ABEO icon

Jennison Associates’s Abeona Therapeutics ABEO Stock Holding History

Jennison Associates’s Portfolio ABEO Stock Details ABEO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-5,656
Closed -$686K – 640
2016
Q4 		$686K Buy
+5,656
New +$886K ﹤0.01% 645

Other funds holding ABEO

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Soros Fund Management New York $8.14B AUM 35.85% 1-Year Est. Return
CHP
Castle Hook Partners New York $21.8B AUM 215.45% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NC
Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Jennison Associates's ABEO Position: Q1 2017 in Review

Jennison Associates sold out of Abeona Therapeutics (ABEO) in Q1 2017, closing a stake of 5,656 shares — an estimated $686K sold.

Jennison Associates first reported a position in ABEO in Q4 2016 and held it in 1 quarter. The position peaked at $686K in Q4 2016. 58 funds tracked by Wall St. Rank hold ABEO as of Q1 2017.

  • Jennison Associates reported no remaining Abeona Therapeutics position as of Q1 2017 after selling out during the quarter.
  • Jennison Associates sold 5,656 Abeona Therapeutics shares in Q1 2017, an estimated $686K.
  • Jennison Associates first reported a position in Abeona Therapeutics in Q4 2016 and held it in 1 quarter.
  • Jennison Associates's Abeona Therapeutics position peaked at $686K in Q4 2016.
  • 58 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2017.

Based on Jennison Associates's 13F filing for Q1 2017, filed 28 Apr 2017.